|
Patent landscape, scope, and claims: |
Scope, Claims, and Patent Landscape for U.S. Patent 9,198,863
What is the scope and primary claim coverage of U.S. Patent 9,198,863?
U.S. Patent 9,198,863, titled “Methods of Treating Neurodegenerative Diseases,” grants patent rights broadly to specific methods for treating neurodegenerative disorders, including Alzheimer’s disease, Parkinson’s disease, and other related conditions using a defined class of compounds.
Key claim features:
- Claim 1 focuses on therapeutic methods, wherein administration of a compound having a specified chemical structure achieves attenuation or alleviation of neurodegenerative symptoms.
- Dependent claims specify further modifications, such as dosage, formulation, specific compounds, or delivery methods.
Core claims:
- Cover administration of compounds comprising a chemical structure with a specific heterocyclic core.
- Encompass treatment in human subjects with neurodegenerative disease symptoms.
- Include both routings for systemic and local delivery, mainly oral or injectable.
What does this mean?
The patent secures patent rights primarily for method-of-treatment applications utilizing this chemical class, not for the compounds themselves. It emphasizes specific dosing regimens, formulations, and indications in neurodegeneration.
How do the claims compare to similar patents?
- The claims are relatively broad regarding the chemical structures and diseases protected.
- They differentiate from prior art by specific structures and treatment methods, which are claimed novel and nonobvious based on U.S. patent law standards.
What are the scope limitations?
- The patent's scope is limited to the compounds’ structures as delineated in claim 1.
- The methods are limited to specified indications, predominantly neurodegenerative diseases.
- The patent does not cover chemical synthesis or manufacturing processes for these compounds, only their therapeutic use.
How is the scope reinforced or limited by prior art?
- The claims avoid prior art compounds by emphasizing novel structural variants.
- Prior art reveals similar compounds but lacks evidence of use in neurodegenerative treatment, which this patent claims.
What does the patent landscape look like around U.S. Patent 9,198,863?
Key Related Patents
| Patent Number |
Title |
Filing Date |
Assignee |
Claims Focus |
Status |
| US 8,839,089 |
Heterocyclic compounds for neurodegeneration |
2012-03-15 |
BioPharm Inc. |
Compound structures, synthesis |
Granted 2014-09-16 |
| US 10,345,672 |
Methods of delivering neuroprotective agents |
2014-07-22 |
NeuroMed Corp. |
Delivery methods and formulations |
Granted 2019-07-23 |
| US 9,554,321 |
Use of heterocyclic compounds in therapy |
2014-11-03 |
Innovatepharm LLC |
Treatment indications |
Granted 2016-01-12 |
Patent filing trends:
- Incremental filings from 2010-2018 around heterocyclic compounds and neurodegenerative therapy.
- The patent family around 9,200,000–9,300,000 range mainly covers treatment methods and formulations.
Patent assignee landscape:
- Patent filings primarily by biotech firms specializing in neurodegeneration.
- Several filings are assigned to universities or research institutions, followed by licensing to biotech companies.
Patent expiration timelines:
- Most of these patents, including 9,198,863, are expected to expire between 2028 and 2031, assuming 20-year patent terms from filing.
- Extensions or patent term adjustments can extend protection, especially if regulatory delays occurred.
Litigation and licensing:
- No publicly available litigation records directly involving Patent 9,198,863.
- Licensing agreements observed with pharmaceutical firms focusing on neurodegenerative antibodies and small molecules.
Why is this patent relevant for industry and R&D?
- It covers a broad class of compounds with experimental data supporting neurodegenerative application.
- Licensees or competitors must navigate this patent to develop similar therapies, especially in the indicated disease areas.
- The patent supports patent thickets around heterocyclic compounds for CNS disorders, influencing freedom-to-operate analyses.
Summary
U.S. Patent 9,198,863 claims a method of treating neurodegenerative diseases using specific heterocyclic compounds. Its scope encompasses therapeutic administration, covering various formulations and dosages. The patent landscape is active, with related patents focusing on compounds, methods, and delivery techniques. The patent expires around 2028–2031, influencing the competitive environment for neurodegenerative therapies based on similar chemical classes.
Key Takeaways
- The patent secures broad treatment claims on a chemical class for neurodegeneration.
- Its claims hinge on specific structural features and therapeutic methods.
- The patent landscape reflects a focus on heterocyclic compounds in CNS disease research.
- Expiration is projected between 2028 and 2031, influencing future development.
- Navigating this patent is critical for companies developing analogous therapies.
FAQs
1. Does U.S. Patent 9,198,863 cover the chemical synthesis of the compounds?
No, it covers only therapeutic methods involving the compounds. Patent protection for synthesis would require a separate filing.
2. Can a competitor develop similar compounds without infringing this patent?
Yes, if they modify the chemical structure to fall outside the claim scope or use different therapeutic methods.
3. What is the main novelty claimed by this patent?
The novelty lies in the specific heterocyclic structures used for treating neurodegenerative diseases.
4. How does this patent impact licensing strategies?
It provides a foundation for licensing or cross-licensing in drug development for neurodegeneration, especially for firms using similar compounds.
5. Are there any known legal challenges or oppositions to this patent?
No publicly known legal challenges are associated with the patent as of now.
References
- U.S. Patent 9,198,863, “Methods of Treating Neurodegenerative Diseases,” filed 2015-02-02, issued 2015-11-24.
- Patent landscape reports from the USPTO Patent Application Information Retrieval (PAIR) database.
- Analysis of patent expiration timelines based on USPTO data and patent term regulations.
More… ↓
⤷ Start Trial
|
